KINASERA — Trusted Streptokinase for Emergency Care

KINASERA — Supporting Faster Thrombolytic Care with Streptokinase

In emergency and critical care settings, rapid thrombolytic treatment can make a significant difference in saving lives and improving patient outcomes. KINASERA, powered by Streptokinase, is designed to support hospitals, physicians, cardiologists, emergency departments, and healthcare professionals with a trusted thrombolytic solution.

KINASERA is available in two strengths to support different medical needs:

• 750,000 IU • 1,500,000 IU

As a thrombolytic agent, Streptokinase is widely used for:

• Acute myocardial infarction management
• Pulmonary embolism treatment
• Deep vein thrombosis (DVT) treatment
• Arterial thrombosis management
• Emergency cardiovascular care
• Critical care and hospital emergency departments

KINASERA helps healthcare professionals respond quickly in urgent situations where timely thrombolytic intervention is essential.

In hospitals, cardiac care units, emergency departments, intensive care units, and vascular centers, thrombolytic therapy remains a vital part of life-saving treatment. Through KINASERA, healthcare providers can access a dependable solution that supports effective clot dissolution and emergency patient care.

At RIHCA / RAWIA INTERNATIONAL HEALTHCARE, we believe that sharing medical awareness and supporting healthcare professionals are essential steps toward building a healthier future.

Serving healthcare sectors across Libya, Iraq, Sudan, Syria, Yemen, Algeria, Tunisia, Morocco, Senegal, Côte d’Ivoire, Cameroon, Chad, Niger, Mali, and other African markets.

To Share. To Care. To Inspire.

KINASERA

Streptokinase

Thrombolytic

AcuteMyocardialInfarction

PulmonaryEmbolism

DVT

Cardiology

EmergencyCare

ICU

HospitalCare

CriticalCare

HealthcareSolutions

PharmaceuticalIndustry

RIHCA

RAWIAINTERNATIONALHEALTHCARE

LibyaHealthcare

AfricaHealthcare

MiddleEastHealthcare